Long-term effects of psychedelic drugs: A systematic review
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. | Neuroscience & Biobehavioral Reviews | 15 March 2020
The Psychedelic Renaissance and Its Forensic Implications
Holoyda, B. | The journal of the American Academy of Psychiatry and the Law | 09 Mar 2020
Collective self-experimentation in patient-led research: How online health communities foster innovation
Kempner, J., & Bailey, J. | Social Science & Medicine | 11 June 2019
Psychedelic drugs-a new era in psychiatry?
Nutt, D. | Dialogues in clinical neuroscience | June 2019
Classic psychedelics: the special role of the visual system
Császár-Nagy, N., Kapócs, G., & Bókkon, I. | Reviews in the neurosciences | 2 April 2019
Psychedelics as anti-inflammatory agents
Flanagan, T. W., & Nichols, C. D. | International Review of Psychiatry | 13 August 2018
Gnosis Potency: DMT Breakthroughs and Paragnosis
St John, G. | Plant Medicines, Healing and Psychedelic Science: Cultural Perspectives | 29 April 2018
Bubbling with Controversy: Legal Challenges for Ceremonial Ayahuasca Circles in the United States
Feeney, K., Labate, B. C., & Hudson, J. H. | Plant Medicines, Healing and Psychedelic Science: Cultural Perspectives | 29 April 2018
Novel psychotherapeutics – a cautiously optimistic focus on Hallucinogens
Sherwood, A. M., & Prisinzano, T. E. | Expert Review of Clinical Pharmacology | 17 December 2017
A regulatory perspective on the evaluation of hallucinogen drugs for human use
Calderon, S. N., Hunt, J., & Klein, M. | Neuropharmacology | 24 November 2017
Regulation of human research with LSD in the United States (1949-1987)
Bonson, K. R. | Psychopharmacology | 17 November 2017
Horizontal gene cluster transfer increased hallucinogenic mushroom diversity
Reynolds, H. T., Vijayakumar, V., Gluck-Thaler, E., Korotkin, H. B., Matheny, P. B., & Slot, J. C. | bioRxiv | 16 August 2017
Peyote as Commodity: An Examination of Market Actors and Access Mechanisms
Feeney, K. | Human Organization | 1 March 2017
Ecstatic Landscapes: The Manifestation of Psychedelic Art
Krippner, S. | Journal of Humanistic Psychology | 20 October 2016
The Psychedelic Policy Quagmire: Health, Law, Freedom, and Society
Van Hagen, A. G. | BJPsych Bull | 11 August 2016
A Public-Health-Based Vision for the Management and Regulation of Psychedelics
Haden, M., Emerson, B., & Tupper, K. W. | Journal of Psychoactive Drugs | 18 July 2016
Ethical Considerations for Clinical Research and Off-label Use of Ketamine to Treat Mood Disorders: The Balance between Risks and Benefits
Zhang, M. W., & Ho, R. C. | Ethics & Behavior | 17 May 2016
“Quite a Profoundly Strange Experience”: An Analysis of the Experiences of Salvia divinorum Users
Hutton, F., Kivell, B., & Boyle, O. | Journal of Psychoactive Drugs | 13 May 2016
How psychoactive drugs shape human culture: a multi-disciplinary perspective
Wadley, G. | Brain Research Bulletin | 12 April 2016
Meta-analysis of executive functioning in ecstasy/polydrug users
Roberts, C. A., Jones, A., & Montgomery, C. | Psychological medicine | 11 March 2016
Psychedelics and cognitive liberty: Reimagining drug policy through the prism of human rights.
Walsh, C. | International Journal of Drug Policy | 12 January
The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity
Kraehenmann, R., Schmidt, A., Friston, K., Preller, K. H., Seifritz, E., & Vollenweider, F. X. | NeuroImage: Clinical | 22 Aug 2015
Noribogaine is a G-Protein Biased κ-Opioid Receptor Agonist
Maillet, E. L., Milon, N., Heghinian, M. D., Fishback, J., Schürer, S. C., Garamszegi, N., & Mash, D. C. | Neuropharmacology | 21 Aug 2015
5-HT2A and mGlu2/3 receptor interactions: on their relevance to cognitive function and psychosis
Wischhof, L., & Koch, M. | Behavioural pharmacology | 19 Aug 2015
Mathematics and mysticism
Abraham, R. | Progress in biophysics and molecular biology | 14 Aug 2015